Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising form of adoptive T-cell immunotherapy for selected hematologic malignancies including leukemia, lymphoma and multiple myeloma. China has become the country with the largest number of registered CAR T-cell trials. Despite the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Wei, Liang, Ai-Bin, Huang, He, Huang, Xiao-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390786/
https://www.ncbi.nlm.nih.gov/pubmed/36794504
http://dx.doi.org/10.3324/haematol.2022.282316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390786/
https://www.ncbi.nlm.nih.gov/pubmed/36794504
http://dx.doi.org/10.3324/haematol.2022.282316

Ejemplares similares